As the overexpression of BCL2 is one of the major contributing factors to the development of multidrug resistance (MDR, a mechanism by which cancer cells resist structurally and mechanistically unrelated chemotherapeutic drugs), BCL2-specific miRNAs can also be used to treat MDR. The gene discussed is BCL2; the disease is cancer.